Pathological changes of the myocardium in reworsening of anthracycline-induced cardiomyopathy after explant of a left ventricular assist device.
Adult
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Cardiomyopathies
/ chemically induced
Cardiotoxicity
Daunorubicin
/ adverse effects
Device Removal
/ adverse effects
Disease Progression
Female
Fibrosis
Heart-Assist Devices
Humans
Idarubicin
/ adverse effects
Leukemia, Promyelocytic, Acute
/ drug therapy
Myocardium
/ pathology
Time Factors
Ventricular Function, Left
anthracycline-induced cardiomyopathy
cardiac pathology
left ventricular assist device
reworsening heart failure
Journal
Nagoya journal of medical science
ISSN: 2186-3326
Titre abrégé: Nagoya J Med Sci
Pays: Japan
ID NLM: 0412011
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
entrez:
11
4
2020
pubmed:
11
4
2020
medline:
29
1
2021
Statut:
ppublish
Résumé
We herein report the long-term changes in cardiac function and pathological findings after successful explantation of a left ventricular assist device in a 42-year-old patient with anthracycline-induced cardiomyopathy with reworsening heart failure. Endomyocardial biopsy samples revealed that the cardiomyocyte diameter decreased and collagen volume fraction increased just after left ventricular assist device explantation. The collagen volume fraction decreased after 6 months, despite preserved systolic function. At 5 years after left ventricular assist device explantation, the systolic function markedly decreased and cardiomyocyte diameter increased. Pathological changes of the myocardium may enable the identification of cardiac dysfunction prior to echocardiographic changes in patients with reworsening heart failure after left ventricular assist device explantation.
Identifiants
pubmed: 32273641
doi: 10.18999/nagjms.82.1.129
pmc: PMC7103868
doi:
Substances chimiques
Idarubicin
ZRP63D75JW
Daunorubicin
ZS7284E0ZP
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
129-134Déclaration de conflit d'intérêts
The authors declare no conflicts of interest associated with this manuscript.
Références
Circulation. 2015 Jun 2;131(22):1981-8
pubmed: 25948538
J Card Fail. 2006 Apr;12(3):227-39
pubmed: 16624689
J Heart Lung Transplant. 2006 Sep;25(9):1091-8
pubmed: 16962471
Prog Cardiovasc Dis. 2016 Jan-Feb;58(4):434-43
pubmed: 26796969
Circ Heart Fail. 2016 Jan;9(1):e002661
pubmed: 26747861
Ann Thorac Surg. 2000 Oct;70(4):1255-8
pubmed: 11081881
Cardiovasc Res. 2005 Dec 1;68(3):376-86
pubmed: 16024006
Cardiovasc Pathol. 2015 Mar-Apr;24(2):128-31
pubmed: 25453728
J Cardiovasc Transl Res. 2010 Dec;3(6):635-42
pubmed: 20820974
J Am Coll Cardiol. 2010 Jan 19;55(3):213-20
pubmed: 20117401
Circ J. 2009 Apr;73(4):741-9
pubmed: 19246810
Circ J. 2008 Sep;72(9):1506-11
pubmed: 18724031
Circulation. 2005 Jul 19;112(3):364-74
pubmed: 15998679
Prog Cardiovasc Dis. 2017 Sep - Oct;60(2):226-236
pubmed: 28551473
Lancet. 2002 Mar 16;359(9310):936-41
pubmed: 11918913